RECRUITING Phase 1 ClinicalTrials.gov

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Sponsor: AbbVie • ClinicalTrials.gov ID: NCT07607964

Registry updated: 2026-10-20

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety of ABBV-519 in adult participants with SLE or RA. This is a single ascending dose study in an estimated 30 adult participants with moderate SLE or RA. The total duration of the study will be approximately 425 days (60-day Screening Period, 1-day Treatment Period, and a 52 week Follow-up Period) at approximately 15 to 20 sites globally. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Interventions

ABBV-519 (Drug)
Intravenous (IV) Infusion
ABBV-519 (Drug)
Subcutaneous (SC) Injection

Eligibility criteria

Inclusion Criteria: Key Inclusion Criteria: * Individuals between 18 and 75 years of age inclusive at the time of Screening. * Minimum baseline B-cell count of 50 cells/mcL. Inclusion Criteria for SLE Participants: * Clinical diagnosis of SLE and fulfilling the 2019 EULAR/ACR classification criteria. * Positive ANA ≥ 1:80 and the presence of at least one of the following autoantibodies above the upper limit of normal (ULN): anti-double-stranded DNA (dsDNA), anti-Smith (Sm), anti-ribonucleoprotein (RNP), or anti-Sjogren's syndrome antigen A (SSA). * Hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score of ≥ 4 (excluding anti-dsDNA and C3/C4). Lupus headache or organic brain syndrome do not count towards the hSLEDAI points required for eligibility. * Participants must have an inadequate response to ≥ 1 immunosuppressant therapies, used for at least 3 months. Inclusion Criteria for RA Participants: * Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA. * Presence of rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPA) above the ULN. * Presence of at least 6 swollen and 6 tender joints * High-sensitivity C-reactive protein (hs-CRP) ≥ 3 mg/L. * Failed at least 1 conventional synthetic disease-modifying antirheumatic drug (DMARD) and ≥ 1 biological or targeted DMARDs of different classes. Exclusion Criteria: Key Exclusion Criteria: * Participants with a history of infection. * Participants with uncontrolled hypertension Exclusion for SLE Participants: * Active neuropsychiatric SLE, or signs or symptoms of neuropsychiatric SLE within the 6 months prior to Screening (lupus headache permissible). \- Unstable or progressive glomerulonephritis (active class III or IV). * SLE overlap syndromes including, but not limited to RA, Sjogren's disease (SjD), SSc, polymyositis, dermatomyositis, or mixed connective tissue disease. Exclusion for RA Participants: \-- History of RA overlap syndromes, including but not limited to SLE, SjD, scleroderma, mixed connective tissue disorder or polymyositis.

Conditions

Systemic Lupus Erythematosus Rheumatoid Arthritis

Locations

Pinnacle Research Group /ID# 278677 — Anniston, Alabama, United States
Solace Research /ID# 279155 — Tustin, California, United States
Clinical Research Of West Florida - Phase I Unit /ID# 279292 — Clearwater, Florida, United States
Finlay Medical Research - Greenacres /ID# 278380 — Greenacres City, Florida, United States
Clinical Research of Osceola /ID# 278374 — Kissimmee, Florida, United States
Allied Biomedical Research Institute /ID# 284408 — Miami, Florida, United States
Discovery Health Research Center /ID# 279691 — Plantation, Florida, United States
Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 279130 — Tampa, Florida, United States
Advanced Quality Medical Research /ID# 279147 — Orland Park, Illinois, United States
West Tennessee Research Institute - Jackson /ID# 284561 — Jackson, Tennessee, United States
Accurate Clinical Research - Houston /ID# 278382 — Houston, Texas, United States
Epic Medical Research /ID# 279180 — Red Oak, Texas, United States
Japan Community Healthcare Organization Chukyo Hospital /ID# 279611 — Nagoya, Aichi-ken, Japan
Institute of Science Tokyo Hospital /ID# 279648 — Bunkyo-ku, Tokyo, Japan
National Center for Global Health and Medicine /ID# 281191 — Shinjuku-ku, Tokyo, Japan

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment